Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years

Bibliographic Details
Main Authors:	Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., Juneja, R.
Format:	Online
Language:	English
Published:	Blackwell Publishing Ltd 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089646/

Similar Items

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
by: Dungan, K. M., et al.
Published: (2016)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
by: Jackson, Robert L, et al.
Published: (2012)

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once‐weekly dulaglutide treatment
by: Umpierrez, G. E., et al.
Published: (2016)

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study
by: Araki, E., et al.
Published: (2015)

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
by: Ferdinand, Keith C., et al.
Published: (2016)

Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme
by: Dungan, K. M., et al.
Published: (2016)

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
by: Weinstock, R. S., et al.
Published: (2015)

Radical Prostatectomy in Korean Men Aged 75-Years or Older: Safety and Efficacy in Comparison with Patients Aged 65–69 Years
by: Ryu, Jae Hyun, et al.
Published: (2016)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study
by: Miyagawa, J., et al.
Published: (2015)

Erno Pretsch 65 Years
by: Bakker, Eric
Published: (2008)

Dialysis outcomes in those aged ≥65 years
by: Walker, Robert, et al.
Published: (2013)

Mortality in Hemodialysis Patients Over 65 Years of Age
by: Coric, Aida, et al.
Published: (2015)

Psychological Treatment of Depression in People Aged 65 Years and Over: A Systematic Review of Efficacy, Safety, and Cost-Effectiveness
by: Jonsson, Ulf, et al.
Published: (2016)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
by: Nauck, Michael, et al.
Published: (2014)

Mammographic screening after the age of 65 years: early outcomes in the Nijmegen programme.
by: van Dijck, J., et al.
Published: (1996)

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
by: Iqbal, Nayyar, et al.
Published: (2014)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson, Angela M, et al.
Published: (2016)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar, Chetan S, et al.
Published: (2013)

HIV infection in elderly (patients aged more than 65 years)
by: Almasi, Farahnaz
Published: (2010)

Laparoscopic Surgery in Elderly Patients Aged 65 Years and Older with Gynecologic Disease
by: Kanasaki, Haruhiko, et al.
Published: (2012)

Polyfluoroalkyl Chemicals and Menopause among Women 20–65 Years of Age (NHANES)
by: Taylor, Kyla W., et al.
Published: (2013)

The National Diet and Nutrition Survey: people aged 65 years and over
by: G., Smithers, et al.
Published: (1998)

Increased mortality after lower extremity fractures in patients <65 years of age
by: Somersalo, Axel, et al.
Published: (2016)

Analysis of spirometry results in hospitalized patients aged over 65 years
by: Wróblewska, Izabela, et al.
Published: (2015)

Incidence of airflow limitation in subjects 65–100 years of age
by: Luoto, Johannes A., et al.
Published: (2016)

The Efficacy and Safety of Microvascular Decompression for Idiopathic Trigeminal Neuralgia in Patients Older Than 65 Years
by: Yang, De-bao, et al.
Published: (2014)

Decline in Titers of Anti-Idiotypic Antibodies Specific to Autoantibodies to GAD65 (GAD65Ab) Precedes Development of GAD65Ab and Type 1 Diabetes
by: Larsson, Helena Elding, et al.
Published: (2013)

Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review
by: Zhang, Lin, et al.
Published: (2016)

65% rakyat Selangor kecewa
by: Zakaria, Faizah Izzani
Published: (2013)

GRASP65 gets the chop
by: Wells, William A.
Published: (2002)

Mammography and women over 65
by: Chandrasekharan, S, et al.
Published: (2002)

Pregnancy at 65, risks and complications
by: Verma, Shailja, et al.
Published: (2016)

Editorial – 65 and counting!
by: Thomas F, Burgess, et al.
Published: (2016)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
by: Odawara, M., et al.
Published: (2016)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
by: Ji, Linong, et al.
Published: (2013)

Ignaz Phillip Semmelweis 1818–65
by: Carter, K. Codell
Published: (1985)

Profiling Mycobacterium ulcerans with hsp65
by: Leão, Sylvia Cardoso, et al.
Published: (2005)

Clinical and epidemiological characteristics of pyogenic liver abscess in people 65 years or older versus people under 65: a retrospective study
by: Jorge Peris, et al.
Published: (2017-07-01)

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
by: Shuichi Suzuki, et al.
Published: (2017-06-01)

Hypercapnic ventilatory response in mice lacking the 65 kDa isoform of Glutamic Acid Decarboxylase (GAD65)
by: Bissonnette, John M, et al.
Published: (2004)